AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10856733
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g/day) added to therapy in group I (n=31)
Trial: 10856733
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group II, n=20) without L-carnitine
Trial: 9062490
Drug: Acipimox (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (oral administration during the last 8 hours)
Trial: 3518499
Drug: Women told
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women told they would be tested for marijuana, alcohol, and other drugs
Trial: 29657206
Drug: Low-dose intradermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intradermal (ID) route: 10 μg of vaccine weekly for 8 weeks (total 40 μg)
Trial: 29657206
Drug: High-dose intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intradermal (ID) route: 40 μg of vaccine at 1-month intervals (total 80 μg)
Trial: 22821660
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy combined with placebo (Control)
Trial: 9236561
Drug: Nefopam hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam hydrochloride, 0.3 mg/kg
Trial: 9236561
Drug: Meperidine hydrochloride,
RxNorm normalized name: Meperidine Hydrochloride, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine hydrochloride, 0.7 mg/kg
Trial: 18294333
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg single dose in CYP2C19*17/*17 subjects
Trial: 18294333
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg single dose in CYP2C19*1/*1 subjects
Trial: 12517462
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (local anaesthetics)
Trial: 8706775
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 2 weeks
Trial: 8706775
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg for 1 week
Trial: 8706775
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg for 1 week
Trial: 25923045
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at three target‐site concentrations: 1, 2, and 3 ng/ml
Trial: 25923045
Drug: Naloxone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (6 μg/kg bolus followed by 0.1 μg/kg/min infusion)
Trial: 25923045
Drug: Remifentanil before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil before and after metoclopramide administration
Trial: 20647058
Drug: Improved medication
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved medication labels
Trial: 17470735
Drug: 2% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% testosterone in Vanicream (10 mg daily)
Trial: 12575232
Drug: nao-yi-an treatment
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nao-yi-an treatment
Trial: 12575232
Drug: medicine control
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medicine control group
Trial: 10319667
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (amoxycillin 500 mg t.i.d., metronidazole 500 mg t.i.d., furoxone 100 mg t.i.d. for 5 days during the 3rd week) + ranitidine 300 mg daily for 8 weeks
Trial: 10319667
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg daily for 12 months
Trial: 7635369
Drug: Lymphocyte immunotherapy
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphocyte immunotherapy (LI) + Progesterone (P)
Trial: 2793265
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg) plus Nifedipine (10 mg)
Trial: 694487
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus granulocyte transfusions (1.7‐14.7 X 10(10) granulocytes by 1‐5 daily transfusions, mean 6.6 X 10(10))
Trial: 30829619
Drug: GDNF (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDNF (administered every 4 weeks for 80 weeks)
Trial: 26130141
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Trial: 26130141
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Trial: 16676701
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (6 mg/kg body mass)
Trial: 10945318
Drug: RIG200 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIG200 (6 nmol/min infusion)
Trial: 10945318
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (0.06 nmol/min infusion)
Trial: 2943050
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ipratropium bromide (200 micrograms three times daily for four weeks)
Trial: 2943050
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ipratropium bromide
Trial: 29387936
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy (CBT) for insomnia
Trial: 23076383
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 10-valent pneumococcal conjugate vaccine (PHiD-CV) and tetravalent meningococcal conjugate vaccine (MenACWY-TT)
Trial: 16627574
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg transdermal nicotine patch (NIC)
Trial: 11045912
Drug: Sildenafil (Viagra)
RxNorm normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (Viagra) 10-100 mg, taken as needed approximately 1 hour prior to sexual activity
Trial: 9193208
Drug: Tizanidine hydrochloride
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine hydrochloride (8 or 16 mg)
Trial: 1553900
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus epirubicin (60 mg/m2 cisplatin + 75 mg/m2 epirubicin)
Trial: 1553900
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus doxorubicin (60 mg/m2 cisplatin + 60 mg/m2 doxorubicin)
Trial: 27445468
Drug: TIO 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO 18 µg
Trial: 20872225
Drug: Pueraria mirifica
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica 25 mg
Trial: 20872225
Drug: Pueraria mirifica
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica 50 mg
Trial: 17448262
Drug: Oral progestogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral progestogens
Trial: 12357478
Drug: Budesonide/formoterol 80/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 80/4.5 microg, two inhalations twice daily (n = 148)
Trial: 12357478
Drug: Budesonide 100
RxNorm normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 100 microg, two inhalations twice daily (n = 138)
Trial: 3135194
Drug: Flumazenil 0.1
RxNorm normalized name: flumazenil 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.1 mg.kg‐1
Trial: 3135194
Drug: Flumazenil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.2 mg.kg‐1
Trial: 11762152
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone replacement therapy (n = 19)
Trial: 11762152
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy (n = 18)
Trial: 11762152
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of oral vs transdermal hormone replacement therapy
Trial: 9407675
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg (2 x ED90)
Trial: 9407675
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg/kg (2 x ED90)
Trial: 8498661
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (SIV)
Trial: 20653677
Drug: Ciclosporin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (5 mg kg(‐1))
Trial: 16960164
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal containing 50 g fat
Trial: 15275751
Drug: ATC dosing
RxNorm normalized name: ATCH (1-24)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATC dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h for 3 days
Trial: 15275751
Drug: PRN dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h PRN for 3 days
Trial: 15275751
Drug: ATC dosing
RxNorm normalized name: ATCH (1-24)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATC dosing of acetaminophen with codeine with nurse coaching (120 mg/12 mg/5 ml) every 4 h for 3 days
Trial: 8495774
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of intranasal nafarelin
Trial: 8495774
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of intranasal nafarelin
Trial: 24055212
Drug: Rotigotine 2
RxNorm normalized name: ROTIGOTINE 2MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 2 mg/24 h
Trial: 24055212
Drug: Rotigotine 3
RxNorm normalized name: ROTIGOTINE 3MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 3 mg/24 h
Trial: 19719796
Drug: Motivationally Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivationally Enhanced (ME) treatment plus Nicotine Replacement Therapy (NRT)
Trial: 19719796
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care (SC) treatment plus Nicotine Replacement Therapy (NRT)
Trial: 9389778
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 200 cm2 area
Trial: 9389778
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 400 cm2 area
Trial: 9389778
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on the largest possible area
Trial: 7958491
Drug: Mild hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Trial: 7958491
Drug: Moderate hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Trial: 22068326
Drug: Pharmacist interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist interventions on antibiotic use
Trial: 19783714
Drug: etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg (days 1‐7)
Trial: 19783714
Drug: etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg (days 8‐14)
Trial: 19783714
Drug: etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg (days 1‐7)
Trial: 17108342
Drug: Target hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1)
Trial: 17108342
Drug: Subnormal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subnormal hemoglobin range (10.5 to 11.5 g per deciliter, group 2)
Trial: 1533090
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral micronized dehydroepiandrosterone
Trial: 1533090
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral micronized dehydroepiandrosterone
Trial: 31176622
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa)
Trial: 31176622
Drug: Luteinising hormone-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising hormone-releasing hormone agonist (LHRHa) alone
Trial: 27258183
Drug: Parkinson disease
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parkinson disease patients walking in medication-off condition
Trial: 19065889
Drug: Compound Tongfu
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Tongfu Granule (CTG)
Trial: 15839187
Drug: Glipizide monotherapy
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide monotherapy
Trial: 8869440
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NS), 2 puffs (2 mg puff-1) administered three times a day via a spacer device and face mask
Trial: 6702646
Drug: Nifedipine (N),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (N), 20 mg, 3 times daily
Trial: 31205087
Drug: R‐spondin1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐spondin1 treatment
Trial: 25136077
Drug: Delayed programming
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed programming (60-second delay before therapy ≥170 beats per minute)
Trial: 19481335
Drug: Daily tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tamoxifen 20mg continuously (daily group)
Trial: 19481335
Drug: Weekly tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Trial: 19481335
Drug: Daily tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tamoxifen 20mg continuously (daily group) and Weekly tamoxifen 20mg after the first 8 weeks of daily treatment (weekly group)
Trial: 17353504
Drug: Exenatide LAR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide LAR 0.8 mg
Trial: 17353504
Drug: Exenatide LAR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide LAR 2.0 mg
Trial: 3619195
Drug: terfenadine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 180 mg
Trial: 2746641
Drug: Single 50‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 50‐mg dose of riboflavin
Trial: 2746641
Drug: More frequent
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More frequent dosage of riboflavin
Trial: 4349414
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from drugs
Trial: 25947394
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Lipo‐PGE1 (Group A)
Trial: 25947394
Drug: No Lipo‐PGE1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Lipo‐PGE1 administration (Group B)
Trial: 21602833
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg once daily plus sildenafil 25‐100 mg on demand (Group A)
Trial: 21602833
Drug: Sildenafil 25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25‐100 mg on demand (Group B)
Trial: 16766780
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (6 gm, caffeine 175 mg)
Trial: 16766780
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (6 gm, caffeine 125 mg)
Trial: 11511821
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 120 mg daily
Trial: 3088275
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of 1% lidocaine
Trial: 3088275
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml of 1% lidocaine
Trial: 3088275
Drug: 0 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml of lidocaine (control)
Trial: 29575803
Drug: TCZ monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ monotherapy
Trial: 27634376
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Trial: 24118531
Drug: Isoproterenol (ISP)
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol (ISP) and adenosine triphosphate (ATP) co-administered before and after circumferential pulmonary vein isolation (CPVI)
Trial: 23253702
Drug: Statins (mainly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (mainly Simvastatin 20 mg and Atorvastatin 10 mg)
Trial: 20855671
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (Esomeprazole, amoxicillin sodium, and clarithromycin) in patients with positive HPSA
Trial: 16884979
Drug: Control (fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fentanyl 30 microg/kg with propofol 2-8 mg/kg/h)
Trial: 3320928
Drug: Cefixime, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime, 8 mg/kg daily for 10 days
Trial: 3320928
Drug: Amoxicillin, 40
RxNorm normalized name: Amoxicillin, 400 mg oral tablet, chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 40 mg/kg/day in three divided doses for 10 days
Trial: 30853490
Drug: l-Carnitine (L-Car)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-Carnitine (L-Car)
Trial: 30853490
Drug: Restricted diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted diet without L-Car
Trial: 30853490
Drug: Restricted diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted diet with L-Car
Trial: 16936417
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) - 2-5 microg/kg subcutaneous injection once daily for 10 days
Trial: 16936417
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow transplantation (BMT) - conventional drug therapy plus BMT
Trial: 10720011
Drug: Diuretic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic administration
Trial: 8707483
Drug: Daily massages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily massages for one month
Trial: 1514711
Drug: captopril 25-50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 25-50 mg twice daily